Variety of qualified clients: CDEC reviewed the uncertainty in the quantity of clients with reasonably significant to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be categorised as acquiring delicate or reasonable illness might have a serious ble